From what 6 stock analysts predict, the share price for Auna SA (AUNA) might decrease by 42.97% in the next year. This is based on a 12-month average estimation for AUNA. Price targets go from $2.96001 to $6.10839. The majority of stock analysts believe AUNA is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 6 Wall Street analysts have assigned AUNA 6 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Auna SA to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on AUNA. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of AUNA.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Joseph Giordano JP Morgan | Overweight | $13 | Maintains | Sep 20, 2024 |
Joseph Giordano JP Morgan | Overweight | $14 | Maintains | Aug 20, 2024 |
Raj Sinha HSBC | Buy | $12.6 | Initiates | Apr 23, 2024 |
Leandro Bastos Citigroup | Buy | $14 | Initiates | Apr 16, 2024 |
Joseph Giordano JP Morgan | Overweight | $16 | Initiates | Apr 16, 2024 |
Mauricio Cepeda Morgan Stanley | Overweight | $14 | Initiates | Apr 16, 2024 |
When did it IPO
2024
Staff Count
14,734
Country
Luxembourg
Sector/Industry
Healthcare/Medical Care Facilities
CEO
Mr. Jesรบs Zamora Leon
Market Cap
$532.9M
In 2023, AUNA generated $3.88B in revenue, which was a increase of 58.10% from the previous year. This can be seen as a signal that AUNA's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Summary - Auna (NYSE: AUNA) reported its unaudited financial results for Q3 2024, covering operations in Mexico, Peru, and Colombia, in accordance with IFRS. Results are in Peruvian Soles.
Why It Matters - Auna's third-quarter financial results provide insights into its performance and growth potential in key Latin American markets, influencing investor sentiment and valuation.
Summary - Auna S.A. (NYSE: AUNA) will release its Q3 2024 financial results on November 19, 2024, after market close, with a conference call on November 20 at 8:00 a.m. ET. Quiet period from Nov 11-19.
Why It Matters - Auna S.A.'s upcoming earnings release and conference call dates signal a critical time for investors to assess financial performance and market outlook, influencing stock valuation and investment decisions.
Summary - Auna S.A. has appointed Laurent Massart as Executive VP of Strategy and Equity Capital Markets, bringing over 25 years of consulting and investment banking experience.
Why It Matters - The appointment of Lorenzo Massart signals a strategic shift for Auna, potentially enhancing its market positioning and growth prospects, which may positively influence investor confidence and stock performance.
Summary - Auna (NYSE: AUNA) reported Q2 2024 earnings per share of 3 cents.
Why It Matters - Auna's Q2 2024 earnings of 3 cents per share provide insight into its financial health, impacting stock performance and investor sentiment.
Summary - Auna (NYSE: AUNA) reported unaudited financial results for Q2 2024, focusing on its operations in Mexico, Colombia, and Peru, with results presented in Peruvian Soles per IFRS standards.
Why It Matters - Auna's financial results for Q2 2024 provide insights into its performance and growth potential in the Latin American healthcare market, impacting investor sentiment and valuation.
Summary - Auna S.A. (NYSE: AUNA) will release Q2 2024 financial results on August 21, 2024, after market close, with a conference call at 5:00 p.m. ET. Quiet period runs from August 2 to August 21.
Why It Matters - Auna S.A.'s upcoming earnings release and conference call are critical for gauging financial performance and market sentiment, impacting stock valuation and investor confidence in the healthcare sector.